Seroatlas · Human Serome Atlas

SLA2

Src-like-adapter 2

Also known as: C20orf156, FLJ21992, SLAP-2, SLAP2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9H6Q3
Gene: SLA2
Ensembl: ENSG00000101082
Chromosome: 20
Canonical length: 261 aa
Protein class: Plasma proteins, Predicted intracellular proteins
Subcellular location: Nucleoplasm,Golgi apparatus,Vesicles

OverviewNCBI Gene

This gene encodes a member of the SLAP family of adapter proteins. The encoded protein may play an important receptor-proximal role in downregulating T and B cell-mediated responses and inhibits antigen receptor-induced calcium mobilization. This protein interacts with Cas-Br-M (murine) ecotropic retroviral transforming sequence c. Two transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

261 residues, UniProt reviewed canonical sequence.

>Q9H6Q3|SLA2
     1  MGSLPSRRKS LPSPSLSSSV QGQGPVTMEA ERSKATAVAL GSFPAGGPAE LSLRLGEPLT
    61  IVSEDGDWWT VLSEVSGREY NIPSVHVAKV SHGWLYEGLS REKAEELLLL PGNPGGAFLI
   121  RESQTRRGSY SLSVRLSRPA SWDRIRHYRI HCLDNGWLYI SPRLTFPSLQ ALVDHYSELA
   181  DDICCLLKEP CVLQRAGPLP GKDIPLPVTV QRTPLNWKEL DSSLLFSEAA TGEESLLSEG
   241  LRESLSFYIS LNDEAVSLDD A

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLA2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.41
Highest tissue expression: 17 nTPM

Expression across tissuesHPA

Tissue

thymus: 17 nTPM
bone marrow: 12 nTPM
lymph node: 9.7 nTPM
tonsil: 8.4 nTPM
spleen: 7.7 nTPM
appendix: 5.3 nTPM

Single-cell type

platelets: 447 nCPM
nk-cells: 258 nCPM
megakaryocytes: 167 nCPM
t-cells: 124 nCPM
pdcs: 97 nCPM
megakaryocyte progenitors: 70 nCPM

Immune cell

plasmacytoid DC: 48 nTPM
NK-cell: 39 nTPM
T-reg: 33 nTPM
naive CD8 T-cell: 31 nTPM
gdT-cell: 29 nTPM
memory CD8 T-cell: 27 nTPM

Brain region

cerebellum: 6.1 nTPM
white matter: 4.1 nTPM
cerebral cortex: 4 nTPM
pons: 3.7 nTPM
amygdala: 3.6 nTPM
medulla oblongata: 3.6 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.73
gnomAD pLI: 0.08
gnomAD missense Z: 0.1
DepMap mean gene effect: 0.11
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

signaling adaptor activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of SLA2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLA2 as an antibody target. Whether an autoantibody or antibody against SLA2 could matter depends on whether native SLA2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLA2 is annotated at the cell surface, where native SLA2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLA2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...